Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy

Carfilzomib is a second-generation proteasome inhibitor approved for the treatment of multiple myeloma (MM). It seems to determine cardiovascular toxicity, primarily arterial hypertension. No predictive factors for cardiovascular adverse events (CVAEs) are known in patients affected by multiple myel...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancers (Basel)
Autori principali: Bruno, Giulia, Bringhen, Sara, Maffei, Ilaria, Iannaccone, Andrea, Crea, Teresa, Ravera, Agnese, Astarita, Anna, Vallelonga, Fabrizio, Salvini, Marco, Gay, Francesca, Veglio, Franco, Milan, Alberto
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6562621/
https://ncbi.nlm.nih.gov/pubmed/31058856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11050622
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi